Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners Co's revenue for the
three
months ended in Mar. 2026 was 円24,115 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円90,392 Mil.
WIN-Partners Co's Revenue per Share for the
three
months ended in Mar. 2026 was 円876.94.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,234.91.
During the past 12 months, the average Revenue per Share Growth Rate of WIN-Partners Co was 15.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, WIN-Partners Co's highest 3-Year average Revenue per Share Growth Rate was 16.60% per year. The lowest was -77.00% per year. And the median was 5.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
WIN-Partners Co Revenue Related Terms
WIN-Partners Co Revenue Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, WIN-Partners Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co Revenue vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's Revenue distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円90,392 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WIN-Partners Co (TSE:3183) has a Revenue of 円90,392 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on WIN-Partners Co and its competitors.
Is WIN-Partners Co's Revenue too high?
WIN-Partners Co's current Revenue is 円90,392 Mil. Overall, WIN-Partners Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's Revenue compare to MCK and COR?
WIN-Partners Co's Revenue of 円90,392 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on WIN-Partners Co and its competitors. WIN-Partners Co's current Revenue is 円90,392 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,534.37, compared to a current price of 円1,265.00 — trading 17.6% below its estimated fair value. The current Revenue is 円90,392 Mil. WIN-Partners Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current Revenue is 円90,392 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,265.00 is trading 17.6% below its estimated GF Value™ of 円1,534.37.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
Revenue: 円90,392 Mil
GF Value™: 円1,534.37 vs. price of 円1,265.00 (17.6% below fair value)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
64GF Score
Get the complete analysis for TSE:3183
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
